Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​Notification of policies going into effect January 1, 2023

November 1, 2022

​The following Independence Blue Cross and Independence Administrators policies went into notification on November 1, 2022, and will become effective on January 1, 2023:

Commercial policies:

  • 00.10.41k: Telemedicine
  • 05.00.69c: Home-Use Light Box Therapy for the Treatment of Seasonal Affective Disorder (SAD)
  • 05.00.80c: Cranial Electrotherapy Stimulation
  • 06.02.30g: Pharmacogenetic Testing to Determine Drug Sensitivity
  • 06.02.44p: Presumptive and Definitive Drug Testing in Substance Abuse and Pain Management Treatments
  • 06.02.55a: Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, or Antiepileptics
  • 07.03.07h: Medical Evaluation and Management for Attention-Deficit Hyperactivity Disorder (ADHD)
  • 07.03.22e: Transcranial Magnetic Stimulation
  • 08.01.37b: Maintenance Treatment of Opioid or Alcohol Dependence Disorder
  • 08.01.80a: Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®)
  • 11.15.16r: Vagus Nerve Stimulation (VNS)
  • 11.15.20q: Deep Brain Stimulation (DBS)
  • 12.01.01bg: Experimental/Investigational
  • 12.04.04b: Acute Care Facility Inpatient Transfers
  • 14.00.01: Electroconvulsive therapy (ECT)
  • 14.00.02: Psychological Testing
  • 14.00.03: Applied Behavioral Analysis (ABA) for the Treatment of Autism Spectrum Disorder (ASD)

Medicare Advantage policies:

  • MA00.005af: Experimental/Investigational
  • MA05.022a: Home-Use Light Box Therapy for the Treatment of Seasonal Affective Disorder (SAD)
  • MA05.066c: Cranial Electrotherapy Stimulation
  • MA06.025p: Presumptive and Definitive Drug Testing in Substance Abuse and Pain Management Treatments
  • MA06.029a: Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, or Antiepileptics
  • MA07.035d: Transcranial Magnetic Stimulation
  • MA08.137a: Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®)
  • MA11.005e: Deep Brain Stimulation (DBS)
  • MA11.019h: Vagus Nerve Stimulation (VNS)
  • MA12.003b: Acute Care Facility Inpatient Transfers
  • MA14.001: Electroconvulsive therapy (ECT)
  • MA14.002: Psychological Testing

For more information, please refer to the Commercial and Medicare Advantage policy notifications published on November 1, 2022. ​

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.